U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07098598) titled 'Pancreatic Cancer Diagnosis With FAPI-PET Imaging' on May 27.
Brief Summary: Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET/CT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and distant metastasis but poor in detecting local lymph node metastasis. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targets FAP, a protein overexp...